SOX2 and gastric cancer: Importantly, MTT assay confirmed that siRNA knockdown of SOX2 in AGSR-CDDP cells—that were previously incubated with a divagated concentration of cisplatin for 24 h—significantly enhanced the cisplatin sensitivity of AGSR-CDDP cells in comparison to the negative control cells (Figure 4B), verifying that SOX2 makes a contribution to developing cisplatin resistance in GC cells.